Associated Papers
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The Cytochrome P450 2C8*3 Variant (rs11572080) Is Associated with Improved Asthma Symptom Control in Children and Altered Lipid Mediator Production and Inflammatory Response in Human Bronchial Epithelial Cells.
Almestica-Roberts M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD et al.
Human Genomics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
G-quadruplex forming sequences in the genes coding for cytochrome P450 enzymes and their potential roles in drug metabolism.
Saad M et al.
Biochimie, 2023
Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F).
Lee YB et al.
International Journal of Molecular Sciences, 2023
Variability of CYP2C8 Polymorphisms in Three Jordanian Populations: Circassians, Chechens and Jordanian-Arabs.
Abudahab S et al.
Journal of Immigrant and Minority Health, 2022
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.
Muñiz P et al.
Frontiers in Immunology, 2022
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A et al.
Journal of Thrombosis and Haemostasis : Jth, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.
Golmohammadzadeh G et al.
Open Access Macedonian Journal of Medical Sciences, 2019
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
Polonikov A et al.
Gene, 2017
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.
Peterson A et al.
Pharmacology Research & Perspectives, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Disease burden and the role of pharmacogenomics in African populations.
Mpye KL et al.
Global Health, Epidemiology and Genomics, 2017
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT et al.
Pharmacological Reviews, 2016
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations.
Szalai R et al.
Drug Metabolism and Pharmacokinetics, 2015
Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation.
Gervasini G et al.
European Journal of Clinical Investigation, 2015
Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C et al.
Drug Metabolism and Pharmacokinetics, 2015
Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.
Lewis T et al.
Clinical Pharmacology and Therapeutics, 2015
Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.
Donnelly MK et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 2015
The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review.
Ng T et al.
Cancer Treatment Reviews, 2014
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL et al.
Breast Cancer Research and Treatment, 2014
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
Umamaheswaran G et al.
The Indian Journal of Medical Research, 2014
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
Aquilante CL et al.
Pharmacotherapy, 2013
Prevalence of CYP2C8 polymorphisms in a North Indian population.
Minhas S et al.
Genetics and Molecular Research : Gmr, 2013
Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.
Yu L et al.
Biopharmaceutics & Drug Disposition, 2013
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.
Arnaldo P et al.
The Malaysian Journal of Medical Sciences : Mjms, 2013
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM et al.
Pharmacology & Therapeutics, 2013
The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
Stringer F et al.
European Journal of Clinical Pharmacology, 2013
CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations.
Wu X et al.
Genetic Testing and Molecular Biomarkers, 2013
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
Genetic polymorphisms of CYP2C8 in the Czech Republic.
Pechandova K et al.
Genetic Testing and Molecular Biomarkers, 2012
Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics.
Sun H et al.
Chemico-biological Interactions, 2011
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S et al.
The Pharmacogenomics Journal, 2011
Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
Jiang H et al.
Amino Acids, 2011
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.
Deenen MJ et al.
The Oncologist, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010